Federal AI Intelligence
Menu
Snapshot · OMB 2025 inventory · processed Oct 11, 2026
VA · VA-24-4513 · record R2184

Clinical Pathways for Cancer Patients

Department of Veterans Affairs · VHA: Veterans Health Administration

Overview

Development stage
In development or acquisitionSource: a) Pre-deployment – The use case is in a development or acquisition status.
High-impact designation
Not high-impactSource: c) Not high-impact
Impact justification
Not reported
Start date
Not reported
Withheld from public reporting
Not reported

Mission

Topic area
Health and Medical
Operational functions
Document processing and extraction, Clinical and medical Derived by keyword rules; see methodology

Problem the AI is intended to solve

The VA National Oncology Program (NOP) has invested in creating clinical pathways that guide providers to provide high quality evidence-based standard of care treatments to Veterans with cancer. However, it is currently unclear how many or how often providers are ‘on pathway’ or are concordant with this recommendation. The work will focus on leveraging AI to assess the degree of adoption of various pathways. For example, the VA NOP proposes to develop, evaluate, and implement an informatics workflow that is capable of extracting information regarding whether a Veteran with prostate cancer has been offered access to germline and somatic genetic testing. This will assess care quality across the VA in terms of genetic testing in Veterans with prostate cancer and provide the necessary information to engage in quality improvement efforts. The work will follow the framework NOP developed to assess germline genetic testing in Veterans with breast cancer, in response to the Advances in Mammography and Medical Options (MAMMO) for Veterans Act of 2022. Briefly, Veterans receiving care for prostate cancer in the VA will be identified using electronic health information in the VA Corporate Data Warehouse and their latest relevant clinical notes will be retrieved.

Expected benefits

Increase efficiency: it will speed up providers' review of patients' treatment plans based on the National Oncology Program guideline, since patients' pathway information will be highlighted. This makes it easier for the providers to make better treatment decisions for the patient, therefore potentially improving patient outcomes.

System outputs

Whether a patient is on a clinical pathway and where on the clinical pathway they are

Technology

AI classification
Natural language processingSource: Natural Language Processing: AI that processes, interprets, and shares information in human language.
System name(s)
Not reported
Custom-developed code
Not reported
Public source code
Not reported

Sourcing

How it was built
Not reported
Vendor (as reported)
Not reported
Vendors (standardized)
None on the standard list

A vendor is the supplier named by the agency. It does not identify the underlying model or AI technology.

Data and privacy

Involves PII
Not reported
Privacy Impact Assessment
Not reported
Authorization to Operate
Not reported
Demographic features
Not reported
Training and evaluation data
Not reported
Federal Data Catalog
Not reported

Governance

0 of 8 minimum-practice questions answered. A blank answer means the agency reported nothing; it does not mean the practice is absent.

Pre-deployment testingNo answer reported
AI impact assessmentNo answer reported
Independent reviewNo answer reported
Ongoing monitoringNo answer reported
Operator trainingNo answer reported
Fail-safeNo answer reported
Appeal processNo answer reported
User and public consultationNo answer reported

Potential impacts and how they were identified

Not reported